doctor head
  pharmacy and drugs  
search Search
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
  doctor legs  


Subscribe to our newsletter:
    Search results
Search results for: levan

1 - 5 of 22 <<previous | next>>

Diseases results:

Bipolar Disorder

Articles results:

BMJ: Drug Company Reports Should Be Read With Caution, Warn Doctors
A study published on today has found that reviews of drugs which are supported by the pharmaceutical industry are less transparent, and are more likely to reach favourable conclusion on drugs, than independent reviews.According to the authors, bias in drug trials is common and often favours the trial-sponsor's product.

SCHWARZ PHARMA Announces Agreement With OTSUKA For Jointly Marketing Pletal In Germany
SCHWARZ PHARMA today announced that SCHWARZ PHARMA Deutschland GmbH has signed an agreement with Otsuka Pharma- ceutical Europe Ltd., UK on the joint marketing of Pletal in Germany. Pletal (cilostazol, developed by Otsuka) is an oral treatment drug for stage II peripheral arterial occlusive disease (intermittent claudication) that has already been proved to be of benefit in the USA, Japan and the UK. This drug is now also available to German patients.

CQ's Carey Discusses Generic Drug Market Entry, Movements To Cover Uninsured U.S. Residents, Genetic Discrimination
Mary Agnes Carey, associate editor of CQ HealthBeat, examines pharmaceutical companies' deals to delay sales of generic prescription drugs, initiatives to expand health insurance coverage and legislation that would ban genetic discrimination in this week's "Health on the Hill from kaisernetwork.

Meeting Highlights From The Committee For Medicinal Products For Human Use (CHMP), 22-24 January 2007
Initial marketing authorisation applicationsThe Committee for Medicinal Products for Human Use (CHMP) gave positive opinions recommending the granting of marketing authorisations for Januvia (sitagliptin) and Xelevia (sitagliptin), from Merck Sharp & Dohme. Both products are intended for the treatment of type-II diabetes mellitus in combination with either metformin or, in certain patients, a PPARg agonist (i.e.

Bayer Settles With 30 States Over Withdrawn Drug Baycol
Thirty states on Monday reached an $8 million settlement agreement with Bayer regarding allegations that the drug company failed to adequately warn consumers about risks associated with its cholesterol-reducing drug Baycol, the

1 - 5 of 22 <<previous | next>>

© 2006-2010 All rights reserved.